𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling

✍ Scribed by Nicola Normanno; Manuela Campiglio; Monica R. Maiello; Antonella De Luca; Mario Mancino; Marianna Gallo; Amelia D’Alessio; Sylvie Menard

Book ID
106377717
Publisher
Springer US
Year
2007
Tongue
English
Weight
408 KB
Volume
112
Category
Article
ISSN
0167-6806

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The MEK/MAPK pathway is involved in the
The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib
✍ Nicola Normanno; Antonella De Luca; Monica R. Maiello; Manuela Campiglio; Maria 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 287 KB 👁 1 views

## Abstract We investigated the role of the MEK/MAPK pathway in the sensitivity/resistance of breast carcinoma cells to the EGFR tyrosine kinase inhibitor gefitinib (IRESSA). We assessed the effects of gefitinib on the growth of three breast cancer cell lines that showed high (SK‐Br‐3; IC~50~ 4 µM)